IGF1R and neoplasm: Two additional anatomical, tumor measurement-based metrics (WHO and RECIST 1.1 criteria) were obtained from the concordant CT of the PET/CT and/or accompanying chest/body CT by an experienced radiologist at baseline (PET/CTBaseline) and within the first cycle of IGF-1R-targeted therapy (PET/CTEarly).